Back to search

Article

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study

2023-07-11

Abstract excerpt

<h4>Background</h4> RECOVER is a multicentre post-approval study of Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pwCF in Ireland and the UK. The CFAbd-Score is the first validated CF-specific patient reported outcome measure (PROM) focusing on gastrointestinal symptoms; it comprises 28 items in 5 domains. In a preliminary study, we previously reported reductions in abdominal symptoms (AS) in pwCF after 26 weeks of ET...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
305bcfd7-7ec1-5bdc-84a7-ca695707fdd8
DOI
10.1101/2023.07.10.23292435
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER studyDOI 10.1101/2023.07.10.23292435
Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaireSemantic proximity
The novel CFAbd-Score.kid<sup>©</sup>reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first resultsSemantic proximity
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.Semantic proximity
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal InflammationSemantic proximity
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.Semantic proximity
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.Semantic proximity
Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis.Semantic proximity
Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients.Semantic proximity
The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosisSemantic proximity
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.Semantic proximity
Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis PatientsSemantic proximity
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity
Select a neighboring publication to make it the new centre.